€250K Italy Investor Visa — AgriTech Opportunity
Invest €250,000 in an Italian AgriTech Startup With a Five-Year Capital-Return Pathway
Qualify for Italy’s €250,000 Investor Visa startup route through a business developing organic crop-protection technology for high-value agriculture.
After five years, investors can use the planned capital-return pathway, with returns capped at 10% IRR, or retain their shares for potential participation in a future acquisition, trade sale or IPO.
The Opportunity
Organic Crop Protection for High-Value Agriculture
The company is developing an organic, bio-rational plant treatment intended for use against bacterial and fungal crop diseases.
The company is developing a naturally derived formulation supported by an expanding patent-application portfolio. The product is being explored for application by conventional spraying and, for trees, through endotherapy: direct injection into the plant’s vascular system.
The initial commercial focus includes olive trees, vines, vegetables and other crops affected by diseases such as Xylella fastidiosa, olive leaf spot, blight, rust, botrytis and mildew.
The company’s identity and detailed materials are made available only following an initial enquiry and suitability review.
Planned Investor Economics
A Defined Five-Year Pathway—or Continued Exposure to a Future Company Exit
Investors may use a planned capital-return mechanism after five years or remain invested for potential participation in a later company exit.
Planned Capital Return
The offer includes a pathway intended to return the investor’s original capital after five years.
Return Under the Five-Year Pathway
Where the planned five-year mechanism is used, the investor’s return is calculated subject to an IRR cap of 10%.
Longer-Term Equity Exposure
Investors may instead retain their shares for potential participation in a future acquisition, trade sale or initial public offering.
The five-year pathway, 10% IRR cap and longer-term exit possibilities are offer features rather than guaranteed outcomes. Their mechanics and applicable conditions should be confirmed against the investment documentation before capital is committed.
The Commercial Context
Crop Disease Creates a Material Need for New Treatment Options
Bacterial and fungal pathogens can damage yields, shorten productive plant life and increase treatment costs across major agricultural markets.
Persistent Plant Disease
Diseases affecting olives, vines, vegetables and other crops create a continuing need for effective prevention and treatment strategies.
Environmental Constraints
Growers and regulators increasingly scrutinise treatment residue, soil impact and reliance on conventional chemical products.
Cost of Application
Broad spraying can involve significant product loss. Targeted delivery may offer a more controlled alternative where technically and commercially suitable.
Product and Development
From Organic Active Ingredient to Scalable Agricultural Product
The proposition combines an organic, bio-rational formulation, disease-focused trials and a planned fermentation-led production model.
Organic, Bio-Rational Formulation
The naturally derived active ingredient has iron-binding, biofilm-inhibition and broader antimicrobial characteristics. The proposition is intended to provide an organic crop-protection alternative while progressing through continuing scientific, regulatory and commercial validation.
Precision Application
Direct tree injection is being tested alongside spraying. The intended benefit is more targeted delivery with less product loss, but performance will depend on crop, pathogen, dosage and field conditions.
International Trial Network
The company reports an independent trial programme extending across Italy, Portugal, France, Spain, the United States and Mexico, covering multiple crops, climates and disease systems.
Production Strategy
The planned production model uses mycelium precision fermentation. Company information refers to discussions with three fermentation laboratories and potential future production activity in Puglia.
Development Progress
Patent, Regulatory and Non-Dilutive Funding Work Is Underway
The company reports material progress across intellectual property, product regulation, international trials and funding routes intended to support the next stage of development.
Patent Applications
The company reports that its UK patent application is pending and its US application has been filed, with three European applications planned as the portfolio develops.
Regulatory Pathway
The regulatory pathway began in September 2026. Current work includes European regulatory engagement and preparation for planned EU and UK submissions.
Non-Dilutive Funding
Multiple grant, research-funding and supported-trial routes have been submitted or are being pursued. Successful awards could fund development while reducing reliance on future dilutive equity capital.
Patent applications are not granted patents, regulatory work does not constitute product approval, and submitted grant applications may not result in funding. Current status can be confirmed through the opportunity information supplied following an enquiry.
How the Investment Works
One Startup Investment With Two Planned Exit Approaches
The €250,000 subscription provides equity exposure to the Italian startup while allowing the investor to consider a planned five-year capital return or a longer holding period.
The five-year pathway, IRR cap and longer-term exit possibilities are features of the offer. They are not guaranteed, and the applicable mechanics should be confirmed in the investment documentation.
Investor Information
What Qualified Prospective Investors Can Request
The current opportunity information provides the detail needed to evaluate the company, investor economics and Investor Visa structure.
Company, Product and Progress
Review the company overview, organic crop-protection proposition, international trial programme, patent applications, regulatory work and production plans.
Investment and Exit Terms
Request the current information covering the equity subscription, planned five-year capital return, 10% IRR cap and longer-term holding option.
Investor Visa Coordination
Understand how the opportunity is intended to fit the €250,000 innovative-startup route and the sequence from programme review to capital deployment.
Investor Visa Sequence
Programme Approval Precedes the Qualifying Investment
The opportunity and the immigration application are connected but distinct. Neither an enquiry nor a share subscription by itself grants Italian residence.
Initial Review
Confirm route fit, nationality, capital availability, timing and high-level source-of-funds position.
Opportunity Review
Request current company, product, financial, registry and investment documents.
Nulla Osta
Submit the online application for programme clearance with the required evidence.
Visa and Permit
Obtain the entry visa, enter Italy and complete the residence-permit procedure.
Capital Deployment
Complete the qualifying investment within the statutory period and maintain it as required.
Investment Considerations
Points to Consider Before Proceeding
The opportunity combines an Investor Visa pathway with equity exposure to a developing agricultural-technology business.
Product Development
Laboratory and field results should be considered alongside the company’s continuing trials, regulatory work and commercialisation plan.
Regulatory Pathway
The regulatory pathway is underway, but commercial deployment remains dependent on the relevant classifications, registrations and approvals in each intended market.
Manufacturing and Scale
The production strategy must translate from trials into reliable, cost-effective supply at commercial scale.
Commercial Adoption
Future value will depend on grower demand, pricing, distribution, repeat purchasing and competitive positioning.
Planned Returns and Exit
The five-year capital-return pathway, 10% IRR cap and alternative longer-term holding strategy should be confirmed against the current investment terms.
Investor Visa Position
The company and transaction must satisfy the applicable innovative-startup route requirements when the application and investment are made.
Specific Opportunity Enquiries
Request the Investor Overview and Planned Exit Terms
Use the form below to request the current information covering the company, organic crop-protection product, €250,000 investment structure, five-year capital-return pathway and longer-term equity option.
GoldenVisas.it will review your enquiry and, where appropriate, facilitate an introduction to the independent programme delivery partner responsible for this opportunity. The partner can respond directly regarding availability, current terms and the next step.
You do not need to make an investment decision before submitting an enquiry.
Information to Request
- Current company overview and product-development status
- Current registry extracts and latest financial information
- Trial summaries and supporting technical evidence
- UK and US patent applications and planned EU filings
- Regulatory pathway and anticipated submission timetable
- Grant applications and non-dilutive funding strategy
- Investment structure and shareholder information
- Five-year capital-return and 10% IRR-cap details
- Longer-term acquisition, trade-sale or IPO pathway
- Use of funds, valuation and capitalisation information
- Investor Visa process and supporting information
GoldenVisas.it is a specialist publisher and introducer and does not receive or hold client investment capital. The company remains unnamed at this stage for commercial confidentiality. Returns and exit outcomes are not guaranteed; current terms should be confirmed before investment.
Specific Opportunity Enquiries
Request the Investor Overview and Current Opportunity Details
Use the form to request current information about this €250,000 organic AgriTech opportunity, including its proposed investment terms, intellectual-property position, regulatory pathway and planned investor exit options.
The provider’s current proposal includes a planned capital-return pathway after five years, with investor returns capped at a 10% IRR. Investors may alternatively remain shareholders for potential participation in a later acquisition, trade sale or IPO.
GoldenVisas.it will review your enquiry and, where appropriate, facilitate an introduction to the independent programme delivery partner responsible for the opportunity. The partner can provide the latest available information and explain the proposed structure directly.
Information Available for Initial Review
- Current investor and company overview
- €250,000 equity-subscription structure
- Planned five-year capital-return and 10% IRR-cap terms
- Longer-term acquisition, trade-sale and IPO pathway
- UK and US patent-application position and planned EU filings
- Product trials and current regulatory timetable
- Grant applications and non-dilutive funding strategy
- Investor Visa implementation and next steps
Proposed returns, funding outcomes and exit scenarios are not guaranteed. Current terms and applicable mechanics should be confirmed against the information supplied before an investment decision is made.